Gabapentin Cannot Navigate Efficacy Hurdles At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Advisory Committee on Reproductive Health Drugs votes overwhelmingly against recommending approval of new indication for severe to moderate vasomotor symptoms, saying the modest effect shown was not sufficient.